SRC and non-small cell lung carcinoma: Linsitinib (2 μM), dasatinib (50 nM), and bemcentinib (100 nM) as monotherapy suppressed phosphorylation of IGF-1R, Src, and AXL, respectively, in H1944 and A549 NSCLC cell lines (Figure S6).